<img height="1" width="1" src="https://www.facebook.com/tr?id=200201724533423&amp;ev=PageView &amp;noscript=1">
Contact Us


    Harmony United Psychiatric Care Enhances Behavioral Health Services with Genomind’s Precision Digital Mental Health Platform

    Audacy Announces Multiplatform Partnership with Digital Mental Health Platform Genomind

    CEO Shawn O'Brien Interviewed on WHBQ56 Sports Radio

    CEO Shawn O'Brien Interviewed on KAHI Radio

    Kevin Love & Genomind Join Forces to Introduce a New Expert Starting Point for Mental Wellness

    Genomind Announces Two Major Appointments

    Genomind Launches GenMed Pro™ Smarter Precision Gene-Drug Interaction Software to Revolutionize the Prescription Process

    Major Advancement in Support for Mental Health Patients as Medicare Provides Coverage of the Genomind Professional PGx Express Test and the VA Extends FSS Contract to Help Soldiers and Veterans

    How pharmacogenetic (PGx) testing is revolutionizing mental health treatment

    Are you susceptible to pandemic-related anxiety?

    Genomind and Stop Soldier Suicide Partner in Mission to Reduce Soldier and Veteran Suicides

    Genomind Announces Major Industry-Leading HLA-A Test Innovation on its Comprehensive Mental Health Pharmacogenetics (PGx) Test, Increasing Utility for Tens of Thousands of Clinicians and Patients

    Genomind Releases Mental Health Map Consumer DNA Test

    Genomind Coordinates With Multiple Health Plans to Expand Access to Its Pharmacogenetics Tools and Help Reduce Mental Health-Related ER and Hospital Visits During the COVID-19 Crisis

    Webinar - How HCPs can shift to telepsychiatry

    Helping You Shift to Telepsychiatry in the Era of COVID-19

    Genomind Launches Express Ship-to-Patient Capability for Genomind Professional PGx Express Test Enabling Access to Critical Mental Health Treatment Information

    Genomind Substantially Increases Customer Access to Pharmacogenetic Mental Health Testing Through Expanded Partnership With Jewel-Osco

    Genomind Expands Collaboration to Provide Access to Genetics-Based Mental Health Test to Customers in All Pennsylvania ACME Markets

    Genomind Joins Forces With Sharecare to Improve Mental Health Outcomes

    Genomind Bolsters Medicare Reimbursement Initiatives, Obtaining Z-Codes for Genomind Professional PGx Express

    Genomind and DrChrono Expand Collaboration to Improve Mental Health Outcomes With Innovative Technology and Services

    Researchers Present New Data on the Utility of Genomind's Mental Health Pharmacogenomic Testing at Upcoming Scientific Conferences

    Genomind Partners with NeuroFlow, Transforming Model of Care for Mental Health Patients

    Genomind Expands Mental Health Genetic Testing Services with New Genomind Professional PGx Express

    The Child Mental Health Crisis

    3 Steps to Help Your Child If They Struggle With Mental Health Issues

    The Child Mental Health Crisis

    3 Steps to Help Your Child If They Struggle With Mental Health Issues

    The Child Mental Health Crisis

    3 Steps to Help Your Child If They Struggle With Mental Health Issues

    Genomind Inc. Recruits Group of World-Renowned Experts in Psychiatry and Neurology to Advance its Commitment to Mental Health Innovation

    Genomind Strengthens its Leadership Team with Hiring of Experienced CEO, President and Internal Promotions

    Genomind to Host Facebook Live Discussion During Mental Health Awareness Week

    Mindful DNA® Professional, Genetic Testing for Personalized Wellness, Forms Wellness Advisory Board of Medical and Research Leaders

    Standard Process Partners With Genomind® To Offer Mindful DNA – A Breakthrough In Personalized Wellness

    Personalized Medicine Advances With First-of-its-Kind Partnership between Genomind® and Albertsons Sav-On, Jewel-Osco and Acme Sav-On

    New research suggests genetic testing may help improve costs associated with mental health treatment

    A Breakthrough in Personalized Wellness: Mindful DNA® Professional Genetic Testing

    Genomind® Patient Gateway Launches as an Easy Way to Access Patient Education and Track Health

    Trio of Awards Cap Ground-Breaking Year for Genomind and Its Unique Platform

    More Americans Than Ever Embrace Genetic Testing To Aid In Mental Health Treatment, According To Annual Genomind® Mental Health Poll™

    Clinicians Gain Powerful New Tool When Treating Patients For Mental Illness: G-DIG, Exclusively From Genomind, Enhances Personalized Medicine

    Multiple Honors and Recognition for Genomind as a Record of Success Continues

    Penguin Random House Publishes Widely Praised Book Authored by Co-Founder of Genomind®

    Genomind's Industry Accolades Expand, Bolstered by a Strong Scientific Advisory Board

    Mental Health Awareness Month: Genomind® Recognizes Psychiatrist Who Made a Difference During Pulse Nightclub Tragedy

    Genomind® Reaches Milestone, Expands Headquarters to Meet Demand

    Genomind® Receives Emerging Company of the Year Award from Life Sciences Pennsylvania

    Genomind® Completes $11 Million Financing to Fund Business Expansion

    Genomind® Looks Forward to Growth in New Year as it Reflects on 2016 Accomplishments

    Clinicians Treating Patients With Depression and Substance Abuse May Find Answers With Genetic Testing

    Recognition Grows for Genomind as a Leader in Genetic Testing for Mental Health Treatment

    Americans Embrace Genetic Testing for Chronic Diseases, Yet Mental Illness Still Lags Behind Others, Survey Finds

    Clinicians Prepare to Learn How Genomind’s Genecept Assay® Can Help in ADHD Treatment

    Genomind Named One of the Best Places to Work in Healthcare

    Genetic Testing for ADHD Patients From Genomind Can Help Them Get Better

    Rep. Brendan Boyle Tour of Genomind Lab In King of Prussia to Showcase Personalized Medicine for Mental Health

    'Dr. Phil' Show to Feature Genomind's Genecept Assay in Upcoming Program Aimed at Helping a Patient Get Better

    Genetic Testing for Mental Health Approved as New Ally for Military Personnel and Veterans

    Clinicians and Patients Gain Powerful Advanced Test for Mental Health as the Genecept Assay Builds on Existing Patient Success

    Genomind's Cutting-Edge Pharmacogenetic Testing To Be Featured On Educational “Innovations” TV Series

    Genomind Appoints New Chief Medical Officer as Personalized Medicine Company Advances Work on Brain Health

    Personalized Medicine for Mental Health Revolutionizes Care as Advocates Mark Mental Illness Awareness Week and World Mental Health Day

    Genomind Secures Latest Round of Financing that Will Solidify Strategic Plan for Company’s Growth

    Genomind is excited to appoint Rina Wolf to its Board of Directors

    Genecept Assay Open Label Trial Results Published In The Primary Care Companion For CNS Disorders

    Genomind Expands And Strengthens Leadership Team

    New Evidence Shows Genetic Testing May Help Target Use of Antidepressants

    Genomind Case Studies Published In Primary Care Companion For CNS Disorders

    Genomind White Paper Describing The Clinical Utility Of Pharmacogenetic Testing In Psychiatry Published In Psychiatry Journal

    Genomind To Exhibit At 2014 NEI Psychopharmacology Congress

    Genomind To Attend The American Academy Of Child & Adolescent Psychiatry (AACAP) Annual Meeting

    Genomind Welcomes New Executive Team Member Thomas Hess

    Genomind Clinical Study Demonstrates effectiveness of the Genecept™ Assay

    Genomind To Exhibit At The APA Annual Meeting And The Clinical TMS Society Meeting

    Genomind Secures Series A Investment Led By Claritas Capital To Fund Growth Of Their Personalized Medicine Company

    ValueOptions And Genomind Announce Innovative Study Of Pharmacogenomic Testing For Treating Psychotic Disorders

    Genomind Announces New Patient Outcomes Data Supporting Use Of The Genecept Assay

    Genomind’s Genetic Testing At Princeton House Promotes Personalized Care

    Genomind To Exhibit At The American Academy Of Anti-Aging (A4M) Congress

    Genomind Announces New Patient Outcomes Data Supporting Use Of The Genecept Assay At NEI Global Psychopharmacology Congress

    Dr. Jay Lombard Of Genomind Selected To Speak At Partnering For Cures (P4C) On “Mental Health: Research And Development At A Crossroads”

    Genomind Announces Licensing Agreement With Emory University To Commercialize Novel Alzheimer’s Risk Biomarkers

    Genomind To Attend and Exhibit At The AACAP Meeting

    Genomind To Participate In APNA Annual Conference

    Genomind Presents New Data Supporting Use Of The Genecept™ Assay At ISCTM

    Genomind Launches New Clinician Portal

    Genomind Demonstrates Broader Commitment To The Mental Health Community

    Genomind Releases Statement Supporting NIMH Announcement To Move Away From DSM Categories

    Genomind Microsite Wins “Best In Class” Award

    Genomind To Participate In NAPHS Annual Meeting

    Genomind To Spend Week Educating Industry Leaders

    Genomind To Exhibit At Two Upcoming Mental Health Conferences

    Genomind Announces New Portal At NEI Global Psychopharmacology Congress

    Genomind Executive To Speak At Open Minds Technology & Informatics Institute

    Rudolph E. Tanzi, Ph.D. Joins Genomind’s Scientific Advisory Board

    Genomind Announces New Scientific Advisory Board Member

    Genomind Welcomes New Executive Team Member Hill Meade

    Genomind To Participate In National Alliance On Mental Illness (NAMI) 2012 National Convention

    Genomind Supports Neuroscience Education Institute (NEI) With Grant To Further Knowledge Of Personalized Medicine Among Health Professionals

    Genomind Supports Massachusetts General Hospital (MGH) Psychiatry Academy With Grant For Live Learning Symposium On Biomarkers In Psychiatry

    Genomind Presents Open Label Study Protocol Designed To Assess The Genecept Assay In Actual Clinical Practice At American Psychiatric Association Annual Meeting

    New Chief Sales Executive To Lead Effort To Expand Adoption Of The Genecept™ Assay

    Dr. Jay Lombard Of Genomind Selected To Speak At TEDMED 2012 On “The New Map For Mental Illness”

    Enhanced Biomarker Test Aids Clinicians With Difficult To Treat Psychiatric Patients

    Genomind Announces New Enhancements To Leadership Team

    Centerstone And Genomind Begin New Study On Genetic Test For Patients With Major Depressive Disorder

    Genomind Announces Inpatient Study With Massachusetts General Hospital Of Genetic Biomarkers In Treatment Resistant Depression

    Schlosspark-Klinik Presents Successful Case History Using Genomind’S Genecept™ Assay At The German Association For Psychiatry And Psychotherapy 2011 Annual Meeting

    Personalized Medicine Offers New Hope To People With Depression

    Pharmacogenetic Testing In Psychiatric Populations Found To Increase Clinician Confidence In Treatment Decisions

    Genecept Assay Increases Clinician Confidence In Treatment Decisions

    Genomind To Present New Results At ISCTM Autumn Conference On “Pharmacogenetic Testing In Psychiatric Populations”

    Genomind Adds Allan I. Levey, Md, Phd, And Anil Malhotra, Md, To Its Scientific Advisory Board

    Genomind Adds Thomas D. Bartel As Chief Sales Officer To Accelerate Successful Commercial Adoption Of The Genecept Assay

    Leading Healthcare Executives Join Genomind To Advance Personalized Medicine In Psychiatry

    Genomind Education Grant To Neuroscience Education Institute (NEI) Explores Genotyping In Psychiatry

    Genomind Presents At 2011 NAMI Convention On Emerging Technologies To Improve Care

    DNA Genotek’s Sample Collection Kit Selected By Genomind For Personalized Medicine Test

    Genomind Presents At NEI Global Psychopharmacology Congress

    Genomind Names Scientific Advisory Board

    Data Collection Completed At Metrocare & Schlosspark

    Genomind Joins Personalized Medicine Coalition

    Genomind Participates In FDA Meetings

    Genomind Lab Partner, PGXL, Selected By National PBM To Provide Tests

    Genomind Announces Partnership with PGXL